Meeting
2021 ASCO Annual Meeting
TP53/NPM1-mutated acute myeloid leukemia as a molecularly distinct disease entity.
Authors
Frank J Scarpa
NeoGenomics Laboratories, Aliso Viejo, CA
Frank J Scarpa , Madhuri Paul , Rachel Daringer , Wendy A. Wolfson , Fernando Lopez Diaz , Sally Agersborg , Vincent Anthony Funari , Lawrence Martin Weiss , Forrest Blocker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7030)
DOI
10.1200/JCO.2021.39.15_suppl.7030
Abstract #
7030
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinical and molecular characteristics of patients with AML with an exceptional response to ivosidenib.
First Author: Justin M. Watts
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2022 ASCO Annual Meeting
Mutational landscape and clinical characterization of over 17,000 patients with myeloid malignancies using real-world data.
First Author: Taylor J. Jensen
Poster
2021 ASCO Annual Meeting
Molecular annotation of extramedullary acute myeloid leukemia to identify prevalence of targetable mutations.
First Author: Somedeb Ball